EFNS task force on management of amyotrophic lateral sclerosis: guidelines for diagnosing and clinical care of patients and relatives: An evidence‐based review with good practice points
Open accessThe DOI matches its Crossref record; 115 of the 115 references it cites were found in a registry or an index.
Abstract
Despite being one of the most devastating diseases known, there is little evidence for diagnosing and managing patients with amyotrophic lateral sclerosis (ALS). Although specific therapy is lacking, correct early diagnosis and introduction of symptomatic and specific therapy can have a profound influence on the care and quality of life of the patient and may increase survival time. This document addresses the optimal clinical approach to ALS. The final literature search was performed in the spring of 2005. Consensus recommendations are given graded according to the EFNS guidance regulations. Where there was lack of evidence but consensus was clear we have stated our opinion as good practice points. People affected with possible ALS should be examined as soon as possible by an experienced neurologist. Early diagnosis should be pursued and a number of investigations should be performed with high priority. The patient should be informed of the diagnosis by a consultant with a good knowledge of the patient and the disease. Following diagnosis, the patient and relatives should receive regular support from a multidisciplinary care team. Medication with riluzole should be initiated as early as possible. PEG is associated with improved nutrition and should be inserted early. The operation is hazardous in patients with vital capacity <50%. Non‐invasive positive pressure ventilation improves survival and quality of life but is underused. Maintaining the patients ability to communicate is essential. During the entire course of the disease, every effort should be made to maintain patient autonomy. Advance directives for palliative end of life care are important and should be fully discussed early with the patient and relatives respecting the patients social and cultural background.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis
Brooks, B. R., Miller, R. G., Swash, M., & Munsat, T. L. (2000) · Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders · doi:10.1080/146608200300079536 · Cited by 5,433 · cited 2×
“Where there was lack of evidence but consensus was clear we have stated our opinion as good practice points.”
BackgroundMethodA Controlled Trial of Riluzole in Amyotrophic Lateral Sclerosis
Bensimon, G., Lacomblez, L., & Meininger, V. (1994) · New England Journal of Medicine · doi:10.1056/nejm199403033300901 · Cited by 2,233
Dose-ranging study of riluzole in amyotrophic lateral sclerosis
Amyotrophic Lateral Sclerosis/Riluzole Study Group II, Lacomblez, L., Bensimon, G., Meininger, V, Leigh, P. N., & Guillet, P. (1996) · The Lancet · doi:10.1016/s0140-6736(96)91680-3 · Cited by 1,301
Self-citationRiluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)
Miller, R. G., Mitchell, J. D., & Moore, D. H. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001447.pub3 · Cited by 1,058
Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)
Miller, R., Mitchell, J., Lyon, M., & Moore, D. (2002) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001447 · Cited by 909
Haverkamp, L. J., Appel, V., & Appel, S. H. (1995) · Brain · doi:10.1093/brain/118.3.707 · Cited by 696
A systematic review of the use of opioids in the management of dyspnoea
Jennings, A.-L. (2002) · Thorax · doi:10.1136/thorax.57.11.939 · Cited by 644
Miller, R. G., Rosenberg, J. A., Gelinas, D. F., Mitsumoto, H., Newman, D., Sufit, R., Borasio, G. D., Bradley, W. G., Bromberg, M. B., Brooks, B. R., et al. (1999) · Neurology · doi:10.1212/wnl.52.7.1311 · Cited by 574
Self-citationVandeKieft, G. K. (2001) · PubMed · Cited by 567
Epidemiology of mutations in superoxide dismutase in amyotrophic lateal sclerosis
Cudkowicz, M. E., McKenna‐Yasek, D., Sapp, P. E., Chin, W., Geller, B., Hayden, D. L., Schoenfeld, D. A., Hosler, B. A., Horvitz, H. R., & Brown, R. H. (1997) · Annals of Neurology · doi:10.1002/ana.410410212 · Cited by 533
Cited by
Kiernan, M. C., Vucic, S., Cheah, B. C., Turner, M. R., Eisen, A., Hardiman, O., Burrell, J. R., & Zoing, M. C. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61156-7 · Cited by 2,603
Self-citationThe EFNS Task Force on Diagnosis and Management of Amyotrophic Lateral Sclerosis:, Andersen, P. M., Abrahams, S., Borasio, G. D., de Carvalho, M., Chio, A., Van Damme, P., Hardiman, O., Kollewe, K., Morrison, K. E., et al. (2012) · European Journal of Neurology · doi:10.1111/j.1468-1331.2011.03501.x · Cited by 1,117
Self-citationMiller, R. G., Jackson, C. E., Kasarskis, E. J., England, J. D., Forshew, D., Johnston, W., Kalra, S., Katz, J. S., Mitsumoto, H., Rosenfeld, J., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181bc0141 · Cited by 807
Clinical genetics of amyotrophic lateral sclerosis: what do we really know?
Andersen, P. M., & Al-Chalabi, A. (2011) · Nature Reviews Neurology · doi:10.1038/nrneurol.2011.150 · Cited by 687
Self-citationMiller, R. G., Jackson, C. E., Kasarskis, E. J., England, J. D., Forshew, D., Johnston, W., Kalra, S., Katz, J. S., Mitsumoto, H., Rosenfeld, J., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181bc01a4 · Cited by 674
Mitchell, J., & Borasio, G. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60944-1 · Cited by 561
Self-citationALSFRS-R score and its ratio: A useful predictor for ALS-progression
Kollewe, K., Mauss, U., Krampfl, K., Petri, S., Dengler, R., & Mohammadi, B. (2008) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2008.07.016 · Cited by 253
Self-citationDiagnosis and management of motor neurone disease
McDermott, C. J., & Shaw, P. J. (2008) · BMJ · doi:10.1136/bmj.39493.511759.be · Cited by 220
Dysarthria in amyotrophic lateral sclerosis: A review
Tomik, B., & Guiloff, R. J. (2010) · Amyotrophic Lateral Sclerosis · doi:10.3109/17482960802379004 · Cited by 201
Self-citationKurt, A., Nijboer, F., Matuz, T., & K??bler, A. (2007) · CNS Drugs · doi:10.2165/00023210-200721040-00003 · Cited by 177
Bede, P., Oliver, D., Stodart, J., van den Berg, L., Simmons, Z., O Brannagain, D., Borasio, G. D., & Hardiman, O. (2011) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2010.232637 · Cited by 123
Self-citationvan Groenestijn, A. C., Kruitwagen-van Reenen, E. T., Visser-Meily, J. M. A., van den Berg, L. H., & Schröder, C. D. (2016) · Health and Quality of Life Outcomes · doi:10.1186/s12955-016-0507-6 · Cited by 92
“Patients suffer progressive wasting and weakness of limb, bulbar and respiratory muscles, leading to inability to speak and swallow, respiratory failure and complete paralysis [1, 2].”
BackgroundAmyotrophic lateral sclerosis and palliative care: where we are, and the road ahead
Blackhall, L. J. (2012) · Muscle & Nerve · doi:10.1002/mus.22305 · Cited by 88
Quality of life of patients with amyotrophic lateral sclerosis
Tramonti, F., Bongioanni, P., Di Bernardo, C., Davitti, S., & Rossi, B. (2012) · Psychology, Health & Medicine · doi:10.1080/13548506.2011.651149 · Cited by 47
“…the motor neurons and causes severe and progressive physical impairment, as well as worsening limitations in the functions of speech, breathing and swallowing (Andersen et al., 2005; Brooks, Miller, Swash, Munsat, & World Federation of Neurology Research Group on Motor Neuron Diseases 2000).”
BackgroundAssociation of APOE with age at onset of sporadic amyotrophic lateral sclerosis
Zetterberg, H., Jacobsson, J., Rosengren, L., Blennow, K., & Andersen, P. M. (2008) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2008.06.025 · Cited by 46
Self-citation
Metadata
- Authors
- Andersen, P. M., Borasio, G. D., Dengler, R., Hardiman, O., Kollewe, K., Leigh, P. N., Pradat, P. ‐., Silani, V., & Tomik, B.
- Venue
- European Journal of Neurology
- Publisher
- Wiley
- Published
- 2005-11-30
- Volume
- 12
- Issue
- 12
- Pages
- 921-938
- ISSN
- 1351-5101 (ISSN-L)
- 1468-1331
- OpenAlex
- W1554056672
- Cited by
- 289
- References
- 115
- FWCI
- 9.88
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.